Remdesivir, dexamethasone and angiotensin-converting enzyme inhibitors use and mortality outcomes in COVID-19 patients with concomitant troponin elevation

Table 2 Descriptive analysis of categorical variable

	Frequency	Percent
Gender
Female	749	41.9%
Male	1039	58.1%
Race
Asian	109	6.1%
Black	81	4.5%
White	1152	64.4%
Others	446	24.9%
Expired
No	1254	70.1%
Yes	534	29.9%
Ventilator use
No	1352	75.6%
Yes	436	24.4%
Intensive care unit
No	1328	74.3%
Yes	460	25.7%
Remdesivir
No	853	49.1%
Yes	883	50.9%
Dexamethasone
No	568	31.8%
Yes	1220	68.2%
Angiotensin converting enzyme inhibitor
No	1441	80.6%
Yes	347	19.4%
Diabetes mellitus
No	1444	80.8%
Yes	344	19.2%
Hypertension
No	1032	57.7%
Yes	756	42.3%
Chronic kidney disease
No	1355	76.0%
Yes	427	24.0%
Acute kidney injury
No	1588	88.8%
Yes	200	11.2%
Congestive heart failure
No	1451	81.2%
Yes	337	18.8%
Chronic obstructive pulmonary disease
No	1678	93.8%
Yes	110	6.2%
Bradycardia
No	823	46.0%
Yes	965	54.0%
Troponin elevation
No	1583	88.5%
Yes	205	11.5%